Keith Katkin
Président chez ELEDON PHARMACEUTICALS, INC.
Fortune : 1 M $ au 30/04/2024
Profil
Keith A.
Katkin is currently serving as the Chairman at Eledon Pharmaceuticals, Inc., an Independent Director at Syndax Pharmaceuticals, Inc., an Independent Director at Emergent BioSolutions, Inc., and a Director at both the Brain Injury Association of America, Inc. and Transposon Therapeutics, Inc. Previously, he held the positions of President, Chief Executive Officer & Director at Avanir Pharmaceuticals, Inc. from 2007 to 2016, President, Chief Executive Officer & Director at Urovant Sciences, Inc. from 2017 to 2020, Chief Executive Officer & Director at Urovant Sciences Ltd.
from 2018 to 2020, Chairman at Otic Pharma Ltd.
from 2015 to 2017, Independent Director at Rigel Pharmaceuticals, Inc. from 2015 to 2022, Independent Class III Director at Carbylan Therapeutics, Inc. from 2014 to 2016, and Vice President-Commercial Development at Peninsula Pharmaceuticals, Inc. from 2004 to 2005.
Mr. Katkin received his undergraduate degree from Indiana University in 1993 and his MBA from Anderson School of Management in 2000.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/03/2024 | 48 000 ( 0,06% ) | 987 360 $ | 30/04/2024 | |
| 23/05/2024 | 59 872 ( 0,11% ) | 127 352 $ | 30/04/2024 | |
| 15/05/2024 | 677 ( 0,00% ) | 1 368 $ | 30/04/2024 |
Postes actifs de Keith Katkin
| Sociétés | Poste | Début |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 29/03/2017 |
| ELEDON PHARMACEUTICALS, INC. | Président | 01/05/2017 |
| EMERGENT BIOSOLUTIONS INC. | Directeur/Membre du Conseil | 01/04/2022 |
| Brain Injury Association of America, Inc. | Directeur/Membre du Conseil | - |
Transposon Therapeutics, Inc.
 Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | Directeur/Membre du Conseil | - |
Anciens postes connus de Keith Katkin
| Sociétés | Poste | Fin |
|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/05/2022 |
| UROVANT SCIENCES LTD. | Directeur Général | 23/03/2020 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Directeur Général | 01/01/2020 |
CoverMyMeds LLC
 CoverMyMeds LLC Life/Health InsuranceFinance CoverMyMeds LLC provides insurance coverage determination forms for drug plans to physicians and pharmacists. The firm integrates with plans using the NCPDP ePA standard, and uses health-plan forms to support an all-plan experience for plans that do not support the NCPDP standard. The company was founded by Sam Rajan and Matt Scantland in 2008 and is headquartered in Columbus, OH. | Directeur/Membre du Conseil | 01/04/2017 |
| ░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Keith Katkin
| Indiana University | Undergraduate Degree |
| Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| ELEDON PHARMACEUTICALS, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
Peninsula Pharmaceuticals, Inc.
 Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Commercial Services |
Carbylan Therapeutics, Inc.
 Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | Health Technology |
Otic Pharma Ltd.
 Otic Pharma Ltd. Pharmaceuticals: MajorHealth Technology Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA. | Health Technology |
CoverMyMeds LLC
CoverMyMeds LLC Life/Health InsuranceFinance CoverMyMeds LLC provides insurance coverage determination forms for drug plans to physicians and pharmacists. The firm integrates with plans using the NCPDP ePA standard, and uses health-plan forms to support an all-plan experience for plans that do not support the NCPDP standard. The company was founded by Sam Rajan and Matt Scantland in 2008 and is headquartered in Columbus, OH. | Finance |
| Brain Injury Association of America, Inc. | |
MC10, Inc.
 MC10, Inc. Medical SpecialtiesHealth Technology MC10, Inc. develops stretchable silicon materials for the microelectronics industry. The firm's technology uses semiconductors in conjunction with interconnect and packaging technologies to produce conformal electronics. It offers solutions for applications in consumer electronics, medical devices, industrial products, defense systems, differentiated consumer products, industrial, and military markets. The company was founded by Carmichael S. Roberts Jr., John A. Rogers, Benjamin Schlatka, Marvin J. Slepian, George M. Whitesides, Gilman Callsen and Roozbeh Ghaffari in 2008 and is headquartered in Lexington, MA. | Health Technology |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | Health Technology |